AGP Picks
View all

WinRho market growth driven by ITP demand and healthcare spending

7 hours ago
WinRho market growth driven by ITP demand and healthcare spending
By AI, Created 00:15 UTC, Nov 20, 2026, AGP -

The WinRho SD market is expanding on steady use in immune thrombocytopenia, Rh prophylaxis and other blood-disorder care, according to a new 2026 report from The Business Research Company. North America led the market in 2025, while the forecast through 2030 points to continued growth as healthcare spending rises and plasma-derived therapies gain wider use.

Why it matters: - WinRho SD, WinRho SDF Liquid and WinRho SDF Lyophilized are tied to treatment areas with recurring clinical demand, including immune thrombocytopenia and Rh prophylaxis. - The market's growth reflects broader pressure for safer plasma-derived products, stronger plasma supply chains and more specialized blood-disorder care. - Download a free sample of the report for the full forecast and supporting data.

What happened: - The Business Research Company published a 2026 market report on WinRho SD, WinRho SDF Liquid and WinRho SDF Lyophilized. - The report says the market showed consistent growth in the historical period and is expected to keep rising through 2030. - North America was the largest regional market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - WinRho products are human plasma-derived immunoglobulins used mainly to prevent Rh immunization in Rh-negative individuals. - The products are also used to treat immune thrombocytopenia and to provide Rh prophylaxis during pregnancy or after incompatible blood transfusions. - The report links past growth to wider adoption of anti-D immunoglobulins, expansion in maternal-fetal medicine, better diagnosis of immune thrombocytopenia, stronger plasma fractionation capacity and routine hospital use. - Future growth is expected to be supported by demand for safer plasma-derived products, more prophylaxis during pregnancy, new investment in plasma collection infrastructure, stronger supply-chain resilience and next-generation immunoglobulin formulations. - The report highlights trends including broader use of plasma-derived immunoglobulin therapies, more Rh prophylaxis, rising use in ITP treatment, greater adoption of lyophilized formats and more focus on plasma safety and traceability. - The report says increasing immune thrombocytopenic purpura diagnoses are a key demand driver. - The report cites US National Institutes of Health data from September 2023 that estimated ITP prevalence in the United States at 9.5 cases per 100,000 people and more than 200,000 cases globally. - The report also points to rising global healthcare spending as a market catalyst. - The UK Office for National Statistics said in May 2024 that healthcare spending rose 5.6% in nominal terms from 2022 to 2023, while long-term health and social care expenditure rose 2.8% in real terms during 2022. - The report says rare blood disorder diagnosis and management are also boosting demand. - Pfizer reported in April 2025 that the UK patient population with hemophilia A and B exceeded 11,800 during 2023-2024. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The report includes a full market report.

Between the lines: - The report frames WinRho demand as part of a larger shift toward plasma-derived therapies that support both acute treatment and preventive care. - The emphasis on traceability, supply resilience and lyophilized formats suggests buyers are weighing manufacturing stability and product handling as much as clinical use. - The regional lead in North America points to an established reimbursement, diagnosis and treatment environment that may be harder for other regions to match quickly.

What's next: - The market's outlook depends on continued ITP detection, sustained healthcare spending and the pace of plasma infrastructure investment. - The report's 2030 forecast suggests the category should remain relevant as immunoglobulin therapy use broadens across blood and immune-system care. - The company is offering sales and expert contact channels for buyers seeking the full dataset and forecasting tools.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Healthcare Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Healthcare Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.